Respiratory Medicine
Volume 104, Issue 4 , Pages 525-533 , April 2010

The clinical utility of long-term humidification therapy in chronic airway disease

  • Harold Rea

      Affiliations

    • University of Auckland, Auckland, New Zealand
    • ,
  • Sue McAuley

      Affiliations

    • Centre for Clinical Research and Effective Practice, Middlemore Hospital, Auckland, New Zealand
    • ,
  • Lata Jayaram

      Affiliations

    • Department of Respiratory Medicine, Middlemore Hospital, Auckland, New Zealand
    • Corresponding Author InformationCorresponding author. Fax: +64 9 2760066.
    • ,
  • Jeffrey Garrett

      Affiliations

    • Department of Respiratory Medicine, Middlemore Hospital, Auckland, New Zealand
    • ,
  • Hans Hockey

      Affiliations

    • Biometrics Matters Ltd, Hamilton, New Zealand
    • ,
  • Louanne Storey

      Affiliations

    • Department of Respiratory Medicine, Middlemore Hospital, Auckland, New Zealand
    • ,
  • Glenis O'Donnell

      Affiliations

    • Centre for Clinical Research and Effective Practice, Middlemore Hospital, Auckland, New Zealand
    • ,
  • Lynne Haru

      Affiliations

    • Centre for Clinical Research and Effective Practice, Middlemore Hospital, Auckland, New Zealand
    • ,
  • Matthew Payton

      Affiliations

    • Fisher and Paykel Healthcare Ltd, New Zealand
    • ,
  • Kevin O'Donnell

      Affiliations

    • Fisher and Paykel Healthcare Ltd, New Zealand

Received 22 September 2009 ,Accepted 28 December 2009.

References 

  1. Bhowmik A, Seemungal TA, Sapsford RJ, Devalia JL, Wedzicha JA. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax. 1998 Nov;53(11):953–956
  2. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847–852
  3. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J. 2008 Feb;31(2):396–406
  4. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J. 1995 Aug;8(8):1333–1338
  5. Rogers DF. Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi Arch Chest Dis. 2000 Aug;55(4):324–332
  6. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, Soler-Cataluna JJ. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005 Aug;128(2):739–745
  7. Wolkove N, Kamel H, Rotaple M, Baltzan MA. Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD. Chest. 2002 Mar;121(3):702–707
  8. Daviskas E, Anderson SD, Gomes K, Briffa P, Cochrane B, Chan K, et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology. 2005;10(1):46–56
  9. Daviskas E, Anderson SD, Young IH, Lassig A, Charlton B. A placebo controlled trial with inhaled mannitol improves health related quality of life in patients with bronchiectasis. Eur Respir J. 2004;24(Suppl. 48):707s
  10. Hasani A, Chapman TH, McCool D, Smith RE, Dilworth JP, Agnew JE. Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis. Chron Respir Dis. 2008;5(2):81–86
  11. Mall MA, Harkema JR, Trojanek JB, Treis D, Livraghi A, Schubert S, et al. Development of chronic bronchitis and emphysema in {beta}-epithelial Na+ channel-overexpressing mice. Am J Respir Crit Care Med. 2008 April;177(7):730–742
  12. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004 Jun;23:932–946
  13. Barker AF. Bronchiectasis. N Engl J Med. 2002 May 2;346(18):1383–1393
  14. Fletcher CMEP, Fairbairn MB, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959;2:257–266
  15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–338
  16. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J Suppl. 1993 Mar;16:5–40
  17. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul;166(1):111–117
  18. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's respiratory questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321–1327
  19. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002 Mar;19(3):398–404
  20. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl. 2002 Sep;37:19s–23s
  21. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003 Jun;41:46s–53s
  22. Groves N, Tobin A. High flow nasal oxygen generates positive airway pressure in adult volunteers. Aust Crit Care. 2007 Nov;20(4):126–131
  23. Brack T, Senn O, Russi EW, Bloch KE. Transtracheal high-flow insufflation supports spontaneous respiration in chronic respiratory failure. Chest. 2005 Jan;127(1):98–104
  24. Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008 Feb;63(2):122–128
  25. Jones P, Higenbottam T. Quantifying of severity of exacerbations in chronic obstructive pulmonary disease: adaptations to the definition to allow quantification. Proc Am Thorac Soc. 2007;4(8):597–601
  26. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007 April;146(8):545–555
  27. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789
  28. Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of action. Respir Med. 2009;103(10):1400–1405
  29. Tsolaki V, Pastaka C, Karetsi E, Zygoulis P, Koutsokera A, Gourgoulianis KI, et al. One-year non-invasive ventilation in chronic hypercapnic COPD: effect on quality of life. Respir Med. 2008 Jun;102(6):904–911
  30. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000 Aug;55(8):635–642

PII: S0954-6111(10)00007-7

doi: 10.1016/j.rmed.2009.12.016

Respiratory Medicine
Volume 104, Issue 4 , Pages 525-533 , April 2010

Article Tools

* Image Usage & Resolution